Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Aspirin-exacerbated Respiratory Disease Clear all
Completed No phase listed Observational

A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only

NCT01631773
View directory record Official record
Conditions
Aspirin-exacerbated Respiratory Disease, Nasal Polyp
Interventions
microRNA
Genetic
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Jul 23, 2026, 12:39 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)

NCT04261582
View directory record Official record
Conditions
Aspirin Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma, Nasal Polyps
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 23, 2026, 12:39 PM EDT
Completed Not applicable Interventional

High Omega-3/Low Omega-6 Treatment Diet for Aspirin-exacerbated Respiratory Disease (AERD)

NCT02064738
View directory record Official record
Conditions
ASA Triad, Asthma, Nasal Polyps, And Aspirin Intolerance
Interventions
Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jul 23, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

NCT01597375
View directory record Official record
Conditions
Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
Interventions
Placebo Oral Tablet, Prasugrel Oral Tablet
Drug
Lead sponsor
Elliot Israel, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jul 23, 2026, 12:39 PM EDT
Completed Phase 4 Interventional Results available

Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

NCT00555971
View directory record Official record
Conditions
Aspirin Sensitivity
Interventions
Omalizumab, placebo
Drug
Lead sponsor
David Lang
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jul 23, 2026, 12:39 PM EDT
Completed No phase listed Observational

Role of Inflammatory Mediators in AERD

NCT02824523
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
aspirin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Jul 23, 2026, 12:39 PM EDT
Not listed Not applicable Interventional

Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

NCT00286416
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
omalizumab (Xolair)
Drug
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2006 · Synced Jul 23, 2026, 12:39 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Mechanisms of Alcohol Sensitivity in AERD

NCT03441438
View directory record Official record
Conditions
Aspirin-Sensitive Asthma With Nasal Polyps, Samter's Syndrome
Interventions
Water, Red wine, Polyphenolic Compounds
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jul 23, 2026, 12:39 PM EDT
Completed Phase 2 Interventional

Mechanisms of Dupilumab in AERD

NCT05031455
View directory record Official record
Conditions
Aspirin-exacerbated Respiratory Disease
Interventions
Aspirin Challenge
Drug
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 23, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

NCT03028350
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
Ifetroban Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Lancaster, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jul 23, 2026, 12:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP

NCT05672030
View directory record Official record
Conditions
Nasal Polyps, Aspirin-exacerbated Respiratory Disease
Interventions
Non-Interventional
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 23, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dupilumab for Aspirin-exacerbated Respiratory Disease

NCT03595488
View directory record Official record
Conditions
Aspirin-exacerbated Respiratory Disease
Interventions
Dupilumab
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jul 23, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Results available

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

NCT02216357
View directory record Official record
Conditions
Aspirin Exacerbated Respiratory Disease (AERD)
Interventions
Ifetroban, Oral Capsule, Placebo, Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Overland Park, Kansas • West Nyack, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jul 23, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

NCT03326063
View directory record Official record
Conditions
Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jul 23, 2026, 12:39 PM EDT
Terminated No phase listed Observational Results available

Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease

NCT01320072
View directory record Official record
Conditions
Asthma, Aspirin-induced
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jul 23, 2026, 12:39 PM EDT
Active, not recruiting Phase 2 Interventional

Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease

NCT05575037
View directory record Official record
Conditions
Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions
Dupilumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 23, 2026, 12:39 PM EDT